Glaucoma is a long-term ocular neuropathy defined by optic disc or retinal nerve fiber structural abnormalities and visual field abnormality. Primary open-angle glaucoma is the most common type of glaucoma. Currently available treatments, initiated in a stepwise process, focus on intraocular pressure (IOP) reduction, and initially include topical drug therapy (single then multidrug combinations), followed by laser then surgical treatment. Topical prostaglandin analogues or beta-adrenergic receptor blockers are first used, followed by alpha-agonists or topical carbonic anhydrase inhibitors, and infrequently, cholinergic agonists and oral therapy. Limitations to existing topical IOP-reducing medications include continued disease progression in glaucoma patients with normal IOP, treatment failure, and low rates of compliance and persistence. Therapeutic agents under investigation include neuroprotectants, which target the disease process manifested by death of retinal ganglion cells, axonal loss, and irreversible loss of vision. Neuroprotectants may be used alone or in combination with IOPreducing therapy (a treatment strategy called complete therapy). Memantine, an N-methyl-D-aspartate receptor blocker currently approved for dementia, is the neuroprotectant farthest along in the process seeking regulatory approval for glaucoma treatment and has a favorable safety profile because of its selective mechanism of action. Several other neuroprotectants are in early stage investigation. Complete therapy provides hope for improved outcomes by reducing the significant morbidity and economic consequences that occur as a result of neurodegeneration and disease progression.
(Am J Manag Care. 2008;14:S20-S27)
The definition and management of glaucoma have changed substantially over the past 3 decades, but several evolving treatment paradigms have not yet moved into clinical practice.1 These include a widespread recognition that glaucoma is a neuropathy of the optic nerve rather than a disease of elevated intraocular pressure (IOP) as well as a diminishing reliance on a minimum IOP as the primary treatment goal.2 Advances in the study of glaucoma neuroprotectants have made these issues more clinically relevant.
Significance of Glaucoma to Managed CareAbout one half of the 2.2 million Americans with open-angle glaucoma are unaware of their disease, since they do not have ocular or systemic symptoms.3-5 The visual impairment resulting from progressive glaucoma is irreversible.6 Loss of peripheral vision, depth perception, and contrast sensitivity associated with this optic neuropathy can have a major effect on an individual’s life.7-12 For example, injuries from automobile accidents and falls because of visual impairments are greater in patients with glaucoma.13-15 End-stage glaucoma is associated with appreciable resource utilization and costs because of the need for both vision rehabilitation and ophthalmology care.16 Glaucoma patients may also be at increased risk for depression.17 These factors may lead to increased costs of care for managing glaucoma as well as for concomitant morbidities.
Despite abundant evidence that early detection and optimal management of glaucoma are the best ways of preserving sight and reducing economic consequences,18,19 the National Committee for Quality Assurance (NCQA) reports that approximately 40% of Medicare beneficiaries enrolled by participating plans do not undergo screening for glaucoma.20 Moreover, as agents used to treat ocular conditions constitute a relatively small proportion of overall pharmaceutical spending, ocular conditions and ophthalmic products remain one of the least managed areas of pharmaceutical care.21
To address these disparities, several health policy and quality-ofcare initiatives have recently been implemented. These include the 2005 Health Plan Employer Data and Information Set measure for glaucoma screening22; expanded glaucoma-specific preventive benefits for Medicare beneficiaries23; and specific glaucoma prevention, detection, and management objectives in Healthy People 2010.24 Glaucoma is primarily a disease of aging,6 and this population is increasingly being covered under managed care plans as a result of the advent of the Medicare Modernization Act of 2003 (known as Medicare Part D). Therefore, managed care decision- makers are reprioritizing glaucoma as a disease that is being actively managed for their covered population.
This article will review the current treatment options for the most common type of glaucoma, known as primary open-angle glaucoma (POAG), explore the rationale for new therapies directed at preventing vision loss (neuroprotectants), and describe a new paradigm in managing POAG using complete therapy directed at the full pathophysiology of the disease.
Clinical Controversy: Beyond IOP
These clinical debates have led to a reassessment of the role of the current treatment options for glaucoma directed at lowering IOP as well as consideration of the need for glaucoma therapies that address the optic neurodegenerative disease processes. Clinical practice guidelines for POAG have been developed by the American Academy of Ophthalmology (AAO),2 although several recent studies have indicated low compliance with these guidelines in various practice sites.49,50 The treatment goals, according to the AAO practice guidelines (2005), include achieving stable optic nerve or retinal fiber layer status, controlled IOP, and stable visual fields while maintaining quality of life.2 Treatment plans are often difficult to implement because the disease is frequently asymptomatic, long term, and typically requires multiple medications.51
The AAO Preferred Practice Pattern notes that laser trabeculoplasty is an appropriate initial therapeutic alternative (Evidence A-I) to topical medications. 2 However, most clinicians initiate with medical therapy, followed by laser, filtering, and cyclodestructive surgery (alone or in combination), and the stepwise process reflects the safety and efficacy of the treatments for the individual patient.2,52
Conventional treatment within typical clinical practice usually begins with the use of topical antiglaucoma medications, with an initial trial in the eye with higher IOP. Pressure measurements are taken, and the clinician attempts to distinguish between therapeutic impact and normal IOP fluctuation. 53 Multiple drug classes may be used, generally added sequentially for their complementary contribution to IOP reduction.2 Examples of eyedrops for first-line therapy include topical cardioselective, beta1-adrenergic (eg, betaxolol) or noncardioselective beta-adrenergic (eg, timolol, levobunolol, metipranolol, carteolol) receptor blockers, or topical prostaglandin analogues (eg, latanoprost, bimatoprost, travoprost, unoprostone).2 Beta-blockers, which reduce IOP by decreasing aqueous humor formation in the eye, are used as first-line treatment because they have relatively few ocular adverse effects, can be used once or twice daily, and do not affect pupil size or accommodation. They may have ocular, respiratory, cardiac, and certain central nervous system side effects.53 Prostaglandin analogues are highly potent at reducing IOP by increasing aqueous humor outflow in the eye. They have few systemic side effects, can be used once daily while maintaining good 24-hour control, and do not affect pupil size or accommodation, although they do have certain adverse ocular effects (eg, iris pigmentation changes, eyelash hypertrichosis, and ocular inflammation). Prostaglandin analogues (specifically bimatoprost, latanoprost, and travoprost) have been shown to be superior, or at least as effective, in reducing IOP as timololol, the gold standard (2003).54-60 In addition, they are theoretically more effective for prevention of acute IOP spikes because of their mechanism for increasing aqueous humor outflow rather than suppressing production.61
Second-line treatments include alpha-agonists (eg, brimonidine) and topical carbonic anhydrase inhibitors (eg, dorzolamide, brinzolamide). They are typically administered 2 to 3 times daily and have few systemic side effects, but they may cause ocular irritation. Alpha-agonists work by increasing uveoscleral outflow of aqueous humor,61 and the newer, more specific alpha2 agonists (eg, brimonidine, apraclonidine) have fewer systemic hypotensive side effects than earlier alpha-adrenergic agonists. Brimonidine is used for long-term sustained therapy, whereas apraclonidine is most useful for short-term adjunctive use.61 Carbonic anhydrase inhibitors decrease aqueous humor production via enzymatic inhibition.61 These may replace or be added to beta-blocker or prostaglandin analogue therapy to further lower IOP.2,52 Combination drugs (eg, beta-blockers with a carbonic anhydrase inhibitor, alpha-agonists, or a prostaglandin analogue) may be used to improve compliance.62
Third- or fourth-line treatments include cholinergic agonists, most commonly pilocarpine or carbachol. These miotic agents lower IOP by increasing conventional trabecular outflow.61 Although efficacious, these parasympathomimetic agents have certain side effects, such as induced myopia and headache, difficulty in evaluating optic disk and visual field because of pupillary constriction and possible cataract formation, cystoid macular edema, or retinal tears or detachments. In addition, these need to be administered 3 or 4 times daily.52 Systemic (orally administered) agents, such as the carbonic anhydrase inhibitors acetazolamide and methazolamide, may be added to the regimen if the IOP is uncontrolled with topical agents or if acute elevations of IOP occur, such as in acute angle-closure glaucoma. Oral carbonic anhydrase inhibitors also have untoward side effects, such as lethargy, loss of appetite, peripheral paresthesias, nephrolithiasis, and potentially fatal aplastic anemia or autoimmune reactions. Epinephrine, a nonspecific adrenergic agonist, is rarely used today, although it has a long history for glaucoma use.61
Several clinical trials have evaluated the use of laser first 63,64 or incisional surgery first,43 and results were comparable to initiating with medical therapy. The selected approach should be based on the risks and benefits of the antiglaucoma medications for a particular patient.2 Laser therapy (trabeculoplasty) may be used to reduce resistance to the outflow of aqueous humor. Surgical therapy includes filtering or cyclodestructive surgery.2 The failure rate of filtering surgery is 20% to 30%, and many patients may require re-operation.2 Cyclodestructive surgery is often reserved for eyes with reduced visual acuity and patients who are poor candidates for incisional surgery, although it is being performed more commonly and does have certain advantages over laser filtration surgery.2
Therapy Failure Leads to Unmet Need
As an optic neuropathy, glaucoma is manifested by death of retinal ganglion cells (RGCs), axonal loss, and an irreversible loss of vision.75 The evolving definition of glaucoma from one of elevated IOP to one characterized by an IOP-sensitive, progressive optic neuropathy has brought a focus on the role of neuroprotectants in the management of the disease process. Such neuroprotectants would not replace but rather would be used in conjunction with IOP-reducing therapy to provide a complete therapy for glaucoma management. Complete therapy including a neuroprotectant would provide doubly targeted treatment for patients with IOPdependent glaucoma. It would also potentially reduce the rate of disease progression in patients with uncontrolled IOP or when progression occurs even with IOP at acceptable levels. If the deleterious consequences of glaucoma progression can be minimized by complete therapy, then the economic and clinical burden of the disease16,76,77 to the patient and payer will be reduced.
Neuroprotectants in Development
Management of POAG is moving beyond a focus on IOP reduction to a recognition that glaucoma is a neurodegenerative disease. With current treatment paradigms, a significant minority of patients experience progression and worsening of the visual field. Existing therapeutic options for glaucoma that are directed at IOP may be complemented by new neuroprotectants that focus on preventing neuronal loss, thereby reducing disease progression and blindness. Memantine is one of the most promising neuroprotectants for glaucoma because it has the most advanced clinical trial data (phase 3) required for FDA approval and has a favorable safety profile as a result of its selective mechanism of action. Complete therapy provides hope that glaucoma outcomes can be improved by reducing the significant morbidity and economic consequences that occur because of neurodegeneration and disease progression.
AcknowledgmentLaurie Kozbelt assisted in the preparation of this manuscript.
Author Affiliations: From Duke University Medical Center, Durham, NC; Goldberg, MD & Associates, Battle Ground, WA; Xcenda, Palm Harbor, FL; Allergan, Inc, Irvine, CA.
Funding Source: The research and manuscript were funded by Allergan, Inc.
Author Disclosures: The authors (SJM, LDG) received honoraria from Allergan, Inc; the author (PP) received compensation from Xcenda, which is a consultant to Allergan, Inc; the author (JGW) is employed by Allergan, Inc; the author (TJB) is employed by Xcenda.
Authorship Information: Concept and design (SJM, LDG, PP, JGW, TJB); acquisition of data (SJM, LDG, PP, JGW, TJB); analysis and interpretation of data (SJM, LDG, PP, JGW, TJB); drafting of the manuscript (SJM, LDG, PP); critical revision of the manuscript for important intellectual content (SMJ, LDG, PP) and supervision (SMJ, LDG, TJB).
Address Correspondence to: Stuart J. McKinnon, MD, PhD, Associate Professor, Departments of Ophthalmology and Neurobiology, Duke University Medical Center, Box 3802, Erwin Road, Durham, NC 27710. E-mail: email@example.com.
1. Quigley HA. New paradigms in the mechanisms and management of glaucoma. Eye. 2005;19:1241-1248.
3. Tielsch JM, Katz J, Singh K, et al. A population-based evaluation of glaucoma screening: the Baltimore Eye Survey. Am J Epidemiol. 1991;134:1102-1110.
5. Friedman DS, Wolfs RC, Oâ€™Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122:532-538.
7. Ringsdorf L, McGwin G Jr, Owsley C. Visual field defects and vision-specific health-related quality of life in African Americans and whites with glaucoma. J Glaucoma. 2006;15:414-418.
9. Sherwood MB, Garcia-Siekavizza A, Meltzer MI, et al. Glaucomaâ€™s impact on quality of life and its relation to clinical indicators. A pilot study. Ophthalmology. 1998;105:561-566.
11. Parrish RK II, Gedde JJ, Scott IU, et al. Visual function and quality of life among patients with glaucoma. Arch Ophthalmol. 1997;115:1447-1455.
13. Glynn RJ, Seddon JM, Krug JH Jr, Sahagian CR, Chiavelli ME, Campion EW. Falls in elderly patients with glaucoma. Arch Ophthalmol. 1991;109:205-210.
15. Haymes SH, LeBlanc RP, Nicolela MT, Chiasson LA, Chauhan BC. Risk of falls and motor vehicle collisions in glaucoma. Invest Ophthalmol Vis Sci. 2007;48:1149-1155.
17. Jampel HD, Frick KD, Janz NK, et al; CIGTS Study Group. Depression and mood indicators in newly diagnosed glaucoma patients. Am J Ophthalmol. 2007;144:238-244.
19. Goldzweig CL, Rowe S,Wenger NS, MacLean CH, Shekelle PG. Preventing and managing visual disability in primary care. JAMA. 2004;291:1497-1502.
21.Yuen J. Ophthalmic agents and managed care. J Manag Care Pharm. 2002;8:217-223.
23. Medicare, Medicaid and SCHIP Benefits Improvement and Protection Act of 2000 (HR 5661). Incorporated in H.R. 4577, the Consolidated Appropriations Act. Congressional Budget Office Pay-As-You-Go Estimate, December 21, 2000. www.cbo.gov/showdoc.cfm?index=3055&sequence=0. Accessed April 11, 2007.
25. Keltner JL, Johnson CA, Anderson DR, et al. The association between glaucomatous visual fields and optic nerve head features in the Ocular Hypertension Treatment Study. Ophthalmology. 2006;113:1603-1612.
27.Weih LM, Nanjan M, McCarty CA,Taylor HR. Prevalence and predictors of open-angle glaucoma: results from the visual impairment project. Ophthalmology. 2001;108:1966-1972.
29. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487-497.
31. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714-720; discussion 829-830.
33. Wax MB, Camras CB, Fiscella RG, Girkin C, Singh K, Weinreb RN. Emerging perspectives in glaucoma: optimizing 24-hour control of intraocular pressure. Am J Ophthalmol. 2002;13(3 suppl):S1-S10.
35. Advanced Glaucoma Intervention Study Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429-440.
38. Varma R,Ying-Lai M, Francis BA, et al. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology. 2004;111:1439-1448.
40. Bengtsson B, Leske MC, Hyman L, Heijl A; Early Manifest Glaucoma Trial Group. Fluctuation of intraocular pressure and glaucoma progression in the Early Manifest Glaucoma Trial. Ophthalmology. 2007;114:205-209.
42. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134-142.
44. Hatt S,Wormald R, Burr J. Screening for prevention of optic nerve damage due to chronic open angle glaucoma. Cochrane Database Syst Rev. 2006;18:CD006129.
46. US Department of Health & Human Services, Centers for Medicare & Medicaid Services. Glaucoma screening. www.cms.hhs.gov/GlaucomaScreening/. Accessed February 5, 2007.
49. Friedman DS, Nordstrom B, Mozaffari E, Quigley HA. Glaucoma management among individuals enrolled in a single comprehensive insurance plan. Ophthalmology. 2005;112:1500-1504.
51. Fiscella RG, Green A, Patuszynski DH, Wilensky J. Medical therapy cost considerations for glaucoma. Am J Ophthalmol. 2003;136:18-25.
53. Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review. Am J Health Syst Pharm. 2005;62:691-699.
55. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 1996;103:138-147.
57. Sherwood M, Brandt J; Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001;45(suppl 4):S361-S368.
59. Hedman K, Alm A, Gross RL. Pooled-data analysis of three randomized double-masked, six-month studies comparing intraocular pressure-reducing effects of latanoprost and timolol in patients with ocular hypertension. J Glaucoma. 2003;12:463-465.
61. Tsai JC, Kanner EM. Current and emerging medical therapies for glaucoma. Expert Opin Emerg Drugs. 2005;10:109-118.
63.The Glaucoma Laser Trial Research Group.The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology. 1990;97:1403-1413.
65. Gurwitz JH, Glynn RJ, Monane M, et al. Treatment for glaucoma: adherence by the elderly. Am J Public Health. 1993;83:711-716.
67. Kosoko O, Quigley HA,Vitale S, Enger C, Kerrigan LA, Tielsch JM. Risk factors for non-compliance with glaucoma follow-up visits. Ophthalmology. 1998;105:2105-2111.
69. Bergea B, Bodin L, Svedbergh B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology. 1999;106:997-1004.
71. Anderson DR, Drance SM, Schulzer M; Collaborative Normal-Tension Glaucoma Study Group. Natural history of normal-tension glaucoma. Ophthalmology. 2001;108:247-253.
73. Araujo SV, Spaeth GL, Roth SM, Starita RJ. A ten-year follow-up on a prospective, randomized trial of postoperative corticosteroids after trabeculectomy.
74.Walland MJ, Carassa RG, Goldberg I, et al. Failure of medical therapy despite normal intraocular pressure. Clin Exp Ophthalmol. 2006;34:827-836.
76. Javitt JC, Zhou Z, Willke RJ. Association between vision loss and higher medical care costs in Medicare beneficiaries: costs are greater for those with progressive
77. Lee PP, Levin LA,Walt JG, et al. Cost of patients with primary open-angle glaucoma: a retrospective study of commercial insurance claims data. Ophthalmology. 2007;114:1241-1247.
79. Namenda [package insert]. New York, NY: Forest Laboratories. www.frx.com/pi/namenda_pi.pdf. Accessed March 17, 2007.
and chronic neurologic insults. NeuroRx. 2004;1:101-110.
82. Mayor-Torroglosa S,WoldeMussie E, Ruiz G, et al. Laser-induced chronic ocular hypertension results in degeneration of retino-tectal afferents: neuroprotection with topical brimonidine. (Abstract). Invest Ophthalmol Vis Sci. 2004;45:877.
84. Fazzone HE, Kupersmith MJ, Leibmann J. Does topical brimonidine tartrate help NAION? Br J Ophthalmol. 2003;87:1193-1194.
86. Zhong L, Bradley J, Schubert W, et al. Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci. 2007;48:
87. Ward MS, Khoobehi A, Lavik EB, Langer R, Young MJ. Neuroprotection of retinal ganglion cells in DBA/2J mice with GDNF-loaded biodegradable microspheres. J Pharm Sci. 2007;96:558-568.
89. Harris A, Arend O, Kagemann L, Garrett M, Chung HS, Martin B. Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma. J Ocul Pharmacol Ther. 1999;15:189-197.
macular degeneration. Prog Retin Eye Res. 1999;18:669-687.
93. Gunvant P, Zheng Y, Essock EA, et al. Predicting subsequent visual field loss in glaucomatous subjects with disc hemorrhage using retinal nerve fiber layer polarimetry. J Glaucoma. 2005;14:20-25.